Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

The US Food and Drug Administration (FDA) has granted priority review to TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle invasive bladder ...

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

Thousands of workers at federal health agencies lost their jobs this week after a US Supreme Court ruling cleared the way for the Trump administration to move forward with major staffing cuts.

Soon, many patients might initiate contact with the health system not by speaking with a call center worker or receptionist, ...

Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers,” researchers wrote.

When researchers used a gene therapy to restore blood vessel health by counteracting the effects of Activin-A, they were able to prevent muscle loss.

The findings of this case series study show substantial variation in the choice of the TNT regimen and were overall aligned with those reported in clinical trials, suggesting the efficacy of TNT in a ...

Biomarker testing rates before first-line treatment increased over time, and rates of biomarker testing increased between first-line and second-line treatment.

Adjuvant chemoradiation combined with camrelizumab was well tolerated and yielded significantly improved long-term survival,” the researchers wrote.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

Amid the growing popularity of cannabis, it is perhaps not surprising that clinicians are increasingly accepting its use among cancer survivors,” the researchers wrote.